Teladoc Stock Declines Ahead of Poor Earnings Outlook
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 2 days ago
0mins
Should l Buy TDOC?
Source: NASDAQ.COM
- Stock Movement: Teladoc (TDOC) ended the recent trading session at $5.10, reflecting a 2.86% decline from the previous day, which underperformed the S&P 500's loss of 0.11%, indicating market concerns about its future performance.
- Monthly Performance: Over the past month, Teladoc's stock has fallen by 2.05%, lagging behind the Medical sector's overall decline of 4.34% and significantly underperforming the S&P 500's gain of 0.51%, highlighting investor pessimism regarding its business outlook.
- Earnings Forecast: The upcoming earnings report is expected to show an EPS of -$0.3, representing a 57.89% year-over-year decline, with revenue projected at $612.3 million, indicating a 2.71% decrease compared to the same quarter last year, reflecting significant profitability challenges.
- Analyst Ratings: Teladoc currently holds a Zacks Rank of #3 (Hold), with a 0.6% upward revision in EPS estimates over the last 30 days; however, the Medical Services industry ranks 143 in Zacks, placing it in the bottom 42%, suggesting overall industry health is concerning.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy TDOC?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on TDOC
Wall Street analysts forecast TDOC stock price to rise
15 Analyst Rating
3 Buy
12 Hold
0 Sell
Hold
Current: 5.250
Low
7.50
Averages
8.91
High
12.00
Current: 5.250
Low
7.50
Averages
8.91
High
12.00
About TDOC
Teladoc Health, Inc. provides virtual healthcare services. Its segments include Teladoc Health Integrated Care (Integrated Care) and BetterHelp. Integrated Care segment includes a suite of global virtual medical services including general medical, expert medical services, specialty medical, chronic condition management, mental health, and enabling technologies and enterprise telehealth solutions for hospitals and health systems. Services in this segment are distributed on a B2B basis. BetterHelp segment includes direct-to-consumer mental health platform. The online counseling and therapy services are provided via its network of over 35,000 licensed clinicians leveraging its platform for Web, mobile app, phone, and text-based interactions. Its Teladoc Health family of brands, including Teladoc and BetterHelp, deliver access to advice and resolution for an array of healthcare needs. Its Telecare brand is a tech-enabled provider of specialist and allied health care via virtual delivery.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Teladoc Stock Declines Ahead of Poor Earnings Outlook
- Stock Movement: Teladoc (TDOC) ended the recent trading session at $5.10, reflecting a 2.86% decline from the previous day, which underperformed the S&P 500's loss of 0.11%, indicating market concerns about its future performance.
- Monthly Performance: Over the past month, Teladoc's stock has fallen by 2.05%, lagging behind the Medical sector's overall decline of 4.34% and significantly underperforming the S&P 500's gain of 0.51%, highlighting investor pessimism regarding its business outlook.
- Earnings Forecast: The upcoming earnings report is expected to show an EPS of -$0.3, representing a 57.89% year-over-year decline, with revenue projected at $612.3 million, indicating a 2.71% decrease compared to the same quarter last year, reflecting significant profitability challenges.
- Analyst Ratings: Teladoc currently holds a Zacks Rank of #3 (Hold), with a 0.6% upward revision in EPS estimates over the last 30 days; however, the Medical Services industry ranks 143 in Zacks, placing it in the bottom 42%, suggesting overall industry health is concerning.
See More
Five-Year Review: April Fool's Portfolio Performance
- Portfolio Returns: The April Fool's Portfolio started with $50,000 in 2021 and grew to $51,380, reflecting a mere 3% increase compared to the S&P 500's 75% total return during the same period, highlighting the impact of market volatility on investments.
- Top Performers: Apple achieved a remarkable 111% return, while Berkshire Hathaway and Intuitive Surgical followed with 86% and 85% returns respectively, indicating these companies' strong competitive positions and robust cash flows even amid market turbulence.
- Underperformers: Stocks like Teladoc, PayPal, Etsy, and Pinterest suffered significant losses due to shifts in consumer behavior post-pandemic and rising interest rates, underscoring the vulnerability of high-valuation stocks in changing market conditions and reminding investors to assess risks carefully.
- Future Investment Strategy: Moving forward, maintaining a diversified portfolio to guard against extreme losses while adhering to a core investment philosophy of low-cost ETFs and shares of proven businesses will help achieve solid returns in turbulent markets.
See More
Teladoc Appoints New Board Member, Stock Rises 6%
- New Board Appointment: Teladoc Health announced the appointment of Susan Salka to its board on Monday, who brings 33 years of experience as the former CEO of AMN Healthcare Services, potentially enhancing strategic oversight and governance.
- Stock Price Surge: Following the announcement, Teladoc's stock rose 6% on Tuesday, indicating a positive market reaction to the new board member, which may bolster investor confidence in the company's future prospects.
- Shareholder Pressure: Pineal Capital sent an open letter to Teladoc's board, criticizing the slow pace of action in key areas, which could expose the company to takeover risks, emphasizing a significant disconnect between current stock price and intrinsic value.
- Value Unlocking Strategy: Pineal Capital urged the board to adopt a plan that includes a $200 million+ share buyback program and a strategic review, potentially breaking up Teladoc's two core businesses to enhance cost efficiencies and maximize shareholder value.
See More
Teladoc Health Appoints New Board Member
- New Board Member: Teladoc Health has appointed former AMN Healthcare CEO Susan Salka to its board of directors, effective immediately, aiming to enhance the company's capabilities in healthcare leadership and governance.
- Extensive Industry Experience: With 33 years at AMN Healthcare, where she drove strategic success and grew revenue to over $5 billion, Salka's insights are expected to significantly contribute to Teladoc's transformation in health outcomes.
- Governance Structure Enhancement: Salka will serve on the board's audit and compensation committees, filling vacancies left by the retirements of Eric Evans and Thomas McKinley, thereby optimizing the governance structure to support future growth.
- Strategic Value Creation: Salka emphasized that integrated, outcomes-focused care is central to creating lasting value, and her addition is anticipated to drive innovation and business expansion for Teladoc in the virtual care sector.
See More
Virtual Health Visits Expected to Surge in Coming Decades
- Market Growth Potential: Virtual health visits are expected to see significant growth over the next decade, addressing the increasing demand for telehealth and driving the digital transformation of the healthcare industry.
- Technology-Driven: As technology advances and user acceptance rises, virtual health services will become more widespread, enhancing patient convenience and accessibility to medical services.
- Investment Opportunities: Healthcare institutions and tech companies are likely to increase investments in virtual health platforms to capitalize on this rapidly growing market, which is expected to create new business models and revenue streams.
- Policy Support: Governments and regulatory bodies may introduce more supportive policies to promote the development of virtual health services, further driving the standardization and regulation of the industry.
See More
TELADOC HEALTH: BARCLAYS LOWERS TARGET PRICE FROM $8.5 TO $7
- Barclays Adjusts Price Target: Barclays has lowered its price target for Teladoc Health from $8.5 to $7.
- Market Implications: This adjustment reflects Barclays' updated outlook on Teladoc's performance in the market.
See More
Teladoc Stock Declines Ahead of Poor Earnings Outlook
- Stock Movement: Teladoc (TDOC) ended the recent trading session at $5.10, reflecting a 2.86% decline from the previous day, which underperformed the S&P 500's loss of 0.11%, indicating market concerns about its future performance.
- Monthly Performance: Over the past month, Teladoc's stock has fallen by 2.05%, lagging behind the Medical sector's overall decline of 4.34% and significantly underperforming the S&P 500's gain of 0.51%, highlighting investor pessimism regarding its business outlook.
- Earnings Forecast: The upcoming earnings report is expected to show an EPS of -$0.3, representing a 57.89% year-over-year decline, with revenue projected at $612.3 million, indicating a 2.71% decrease compared to the same quarter last year, reflecting significant profitability challenges.
- Analyst Ratings: Teladoc currently holds a Zacks Rank of #3 (Hold), with a 0.6% upward revision in EPS estimates over the last 30 days; however, the Medical Services industry ranks 143 in Zacks, placing it in the bottom 42%, suggesting overall industry health is concerning.
See More
Five-Year Review: April Fool's Portfolio Performance
- Portfolio Returns: The April Fool's Portfolio started with $50,000 in 2021 and grew to $51,380, reflecting a mere 3% increase compared to the S&P 500's 75% total return during the same period, highlighting the impact of market volatility on investments.
- Top Performers: Apple achieved a remarkable 111% return, while Berkshire Hathaway and Intuitive Surgical followed with 86% and 85% returns respectively, indicating these companies' strong competitive positions and robust cash flows even amid market turbulence.
- Underperformers: Stocks like Teladoc, PayPal, Etsy, and Pinterest suffered significant losses due to shifts in consumer behavior post-pandemic and rising interest rates, underscoring the vulnerability of high-valuation stocks in changing market conditions and reminding investors to assess risks carefully.
- Future Investment Strategy: Moving forward, maintaining a diversified portfolio to guard against extreme losses while adhering to a core investment philosophy of low-cost ETFs and shares of proven businesses will help achieve solid returns in turbulent markets.
See More
Teladoc Appoints New Board Member, Stock Rises 6%
- New Board Appointment: Teladoc Health announced the appointment of Susan Salka to its board on Monday, who brings 33 years of experience as the former CEO of AMN Healthcare Services, potentially enhancing strategic oversight and governance.
- Stock Price Surge: Following the announcement, Teladoc's stock rose 6% on Tuesday, indicating a positive market reaction to the new board member, which may bolster investor confidence in the company's future prospects.
- Shareholder Pressure: Pineal Capital sent an open letter to Teladoc's board, criticizing the slow pace of action in key areas, which could expose the company to takeover risks, emphasizing a significant disconnect between current stock price and intrinsic value.
- Value Unlocking Strategy: Pineal Capital urged the board to adopt a plan that includes a $200 million+ share buyback program and a strategic review, potentially breaking up Teladoc's two core businesses to enhance cost efficiencies and maximize shareholder value.
See More
Teladoc Health Appoints New Board Member
- New Board Member: Teladoc Health has appointed former AMN Healthcare CEO Susan Salka to its board of directors, effective immediately, aiming to enhance the company's capabilities in healthcare leadership and governance.
- Extensive Industry Experience: With 33 years at AMN Healthcare, where she drove strategic success and grew revenue to over $5 billion, Salka's insights are expected to significantly contribute to Teladoc's transformation in health outcomes.
- Governance Structure Enhancement: Salka will serve on the board's audit and compensation committees, filling vacancies left by the retirements of Eric Evans and Thomas McKinley, thereby optimizing the governance structure to support future growth.
- Strategic Value Creation: Salka emphasized that integrated, outcomes-focused care is central to creating lasting value, and her addition is anticipated to drive innovation and business expansion for Teladoc in the virtual care sector.
See More
Virtual Health Visits Expected to Surge in Coming Decades
- Market Growth Potential: Virtual health visits are expected to see significant growth over the next decade, addressing the increasing demand for telehealth and driving the digital transformation of the healthcare industry.
- Technology-Driven: As technology advances and user acceptance rises, virtual health services will become more widespread, enhancing patient convenience and accessibility to medical services.
- Investment Opportunities: Healthcare institutions and tech companies are likely to increase investments in virtual health platforms to capitalize on this rapidly growing market, which is expected to create new business models and revenue streams.
- Policy Support: Governments and regulatory bodies may introduce more supportive policies to promote the development of virtual health services, further driving the standardization and regulation of the industry.
See More
TELADOC HEALTH: BARCLAYS LOWERS TARGET PRICE FROM $8.5 TO $7
- Barclays Adjusts Price Target: Barclays has lowered its price target for Teladoc Health from $8.5 to $7.
- Market Implications: This adjustment reflects Barclays' updated outlook on Teladoc's performance in the market.
See More
